Senior Scientist and Director for Health Services Research and Implementation Science, Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA
Research Associate Professor of Medicine, Keck School of Medicine of USC, Los Angeles, CA
Michael K. Gould, MD, MS is a nationally-recognized expert in lung cancer screening and pulmonary nodule evaluation. He is currently a Senior Scientist and Director for Health Services Research and Implementation Science in the Department of Research and Evaluation (R&E) at Kaiser Permanente Southern California (KPSC), where he also leads the Care Improvement Research Team (CIRT). The CIRT is deeply embedded in the clinical environment at KPSC and is currently working with operational leaders on several projects involving the implementation of lung cancer screening. Before moving to R&E, Dr. Gould was a practicing pulmonologist for over 13 years, first at the VA Palo Alto Health Care System and subsequently at the USC/Norris Comprehensive Cancer Center, where he cared for patients with lung cancer and respiratory complications of other cancers. He is Editor of the American College of Chest Physicians (ACCP) guidelines for evaluating pulmonary nodules, and a member of the Multi-Society Lung Cancer Screening Guidelines Panel. Dr. Gould has used meta-analysis, decision analysis, cost-effectiveness analysis, and multivariate statistical analysis to study multiple domains of health care quality in patients with lung cancer and pulmonary nodules. He recently completed a NCI-funded study of computerized decision support for lung nodule evaluation, which showed that decision support resulted in only small improvements in diagnosis and management.
- Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-53.
- Aberle DR, Adams AM, et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 2010;102:1771-9.
- Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29.
- Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. New England Journal of Medicine 2015;372:387-388.
- de Koning HJ, Meza R, Plevritis SK, et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Programs for High-Risk Populations. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
- Humphrey LL, Deffebach M, Pappas M, Zakher B, Slatore CG. Screening for lung cancer with low-dose computed tomography. Ann Intern Med 2014;160:212.
- Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54.